UY31361A1 - Vacunas y componentes para inhibir celulas microbianas - Google Patents

Vacunas y componentes para inhibir celulas microbianas

Info

Publication number
UY31361A1
UY31361A1 UY31361A UY31361A UY31361A1 UY 31361 A1 UY31361 A1 UY 31361A1 UY 31361 A UY31361 A UY 31361A UY 31361 A UY31361 A UY 31361A UY 31361 A1 UY31361 A1 UY 31361A1
Authority
UY
Uruguay
Prior art keywords
peptides
polypeptides
polynucleotides
microbial cells
antibodies
Prior art date
Application number
UY31361A
Other languages
English (en)
Inventor
Leahy Sinead
Kong Zhanhao
Kelly William John
Dong Li
Attwood Graeme Trevor
Altermann Eric Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31361A1 publication Critical patent/UY31361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/20—Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
    • Y02P60/22—Methane [CH4], e.g. from rice paddies

Abstract

La invención incluye componentes de células microbianas que son útiles para producción de anticuerpos, incluyendo péptidos, polipéptidos que comprenden estos péptidos, polinucleótidos que codifican estos péptidos o polipéptidos, y anticuerpos dirigidos a estos péptidos, polipéptidos o polinucleótidos. La invención también incluye vectores de expresión y células huésped para producir estos péptidos, polipéptidos, polinucleótidos y anticuerpos. La invención además incluye métodos y composiciones, especialmente composiciones de vacunas, para detectar, dirigir e inhibir células microbianas, especialmente células metanógenas, usando uno o más de los péptidos, polipéptidos, polinucleótidos, anticuerpos, vectores de expresión y células huésped revelados.
UY31361A 2007-09-25 2008-09-25 Vacunas y componentes para inhibir celulas microbianas UY31361A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97510407P 2007-09-25 2007-09-25
US98984107P 2007-11-22 2007-11-22
US98984007P 2007-11-22 2007-11-22

Publications (1)

Publication Number Publication Date
UY31361A1 true UY31361A1 (es) 2009-04-30

Family

ID=40511642

Family Applications (3)

Application Number Title Priority Date Filing Date
UY31360A UY31360A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizadores de celulas para celulas microbianas
UY31359A UY31359A1 (es) 2007-09-25 2008-09-25 Polinucleotidos y polipeptidos del fago qmru y sus usos
UY31361A UY31361A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes para inhibir celulas microbianas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
UY31360A UY31360A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizadores de celulas para celulas microbianas
UY31359A UY31359A1 (es) 2007-09-25 2008-09-25 Polinucleotidos y polipeptidos del fago qmru y sus usos

Country Status (17)

Country Link
US (7) US9296789B2 (es)
EP (5) EP2203467B1 (es)
JP (5) JP5558356B2 (es)
CN (4) CN102015755A (es)
AR (3) AR068553A1 (es)
AU (4) AU2008304019A1 (es)
BR (5) BR122021010737B1 (es)
CA (3) CA2700164C (es)
CL (3) CL2008002859A1 (es)
DK (3) DK2203467T3 (es)
ES (3) ES2895908T3 (es)
MX (3) MX2010003321A (es)
NZ (1) NZ745324A (es)
RU (1) RU2528854C2 (es)
UY (3) UY31360A1 (es)
WO (3) WO2009041831A1 (es)
ZA (1) ZA201001933B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203467B1 (en) 2007-09-25 2016-12-14 Pastoral Greenhouse Gas Research LTD Phage -mru polynucleotides and polypeptides and uses thereof
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
KR101701890B1 (ko) * 2009-06-26 2017-02-02 뤼산도 아게 항균제
ES2579806T3 (es) * 2009-06-26 2016-08-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Agentes antimicrobianos
BR112012004308A2 (pt) * 2009-08-27 2015-09-01 Pastoral Greenhouse Gas Res Ltd Sequência do genoma completo do metanógeno methanobrevibacter ruminantium
BR112012026880B1 (pt) * 2010-04-27 2021-03-16 Lysando Ag método para eliminação ou redução de um biofilme bacteriano, variante de endolisina ou variante de bacteriocina e seus usos
KR102362341B1 (ko) * 2012-09-19 2022-02-14 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2014144592A2 (en) 2013-03-15 2014-09-18 The General Hospital Corporation Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
LT3066201T (lt) 2013-11-07 2018-08-10 Editas Medicine, Inc. Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
EP3215611B1 (en) * 2014-11-06 2019-08-21 E. I. du Pont de Nemours and Company Peptide-mediated delivery of rna-guided endonuclease into cells
CN104789675A (zh) * 2015-04-15 2015-07-22 江苏师范大学 一种检测荷斯坦奶牛瘤胃微生物的方法
WO2016178207A1 (en) * 2015-05-04 2016-11-10 Ramot At Tel-Aviv University Ltd. Methods and kits for fragmenting dna
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US20190292514A1 (en) * 2016-07-14 2019-09-26 Basf Se Fermentation medium comprising chelating agent
EP3565904A1 (en) * 2016-12-29 2019-11-13 Illumina, Inc. Analysis system for orthogonal access to and tagging of biomolecules in cellular compartments
CN112986589B (zh) * 2017-01-05 2023-01-24 深圳迈瑞生物医疗电子股份有限公司 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
US10745439B2 (en) * 2017-03-20 2020-08-18 Regents Of The University Of Minnesota Kinase substrates and methods of use thereof
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
KR102647714B1 (ko) * 2018-03-19 2024-03-18 리제너론 파마슈티칼스 인코포레이티드 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
EP3880227A4 (en) * 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. CD25 ANTIBODIES
CN109627301B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin固体稳定剂开发及应用
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
EP4037666B1 (en) 2020-12-08 2024-05-01 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113121705B (zh) * 2021-04-19 2023-03-24 成都英普博集生物科技有限公司 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用
US20240009291A1 (en) * 2022-07-11 2024-01-11 Arkea Bio Corp. Compositions and methods for reducing methane emissions in ruminant populations
CN115938486B (zh) * 2022-12-06 2023-11-10 内蒙古农业大学 基于图神经网络的抗菌性乳酸菌株筛选方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159861A (en) * 1875-02-16 Improvement in brooms
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
EP0150186A1 (fr) * 1983-05-03 1985-08-07 S.S.M. International Chemical Company Limited Composition a activite pharmaceutique amelioree et utilisation decelle-ci pour des usages veterinaires
GB8815968D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Veterinary devices
JPH05219927A (ja) * 1992-02-14 1993-08-31 Gumma Pref Gov 飼料の混合装置及び混合飼料の製造方法
JP3651915B2 (ja) * 1993-06-30 2005-05-25 財団法人神奈川科学技術アカデミー シグナル配列ペプチドをコードするｄｎａ断片の探索法及びそのためのベクター
EP0724454B1 (en) * 1993-10-19 2004-03-24 Commonwealth Scientific And Industrial Research Organisation Method for improving utilisation of nutrients by ruminant or ruminant-like animals
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
NZ278977A (en) 1994-01-20 1997-03-24 Pastoral Agric Res Inst Nz Ltd Sustained release bolus for ruminants
JPH09508117A (ja) 1994-01-20 1997-08-19 ニュージーランド パストラル アグリカルチャー リサーチ インスティテュート リミティド 反芻動物に有益な物質を投与するための器具
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
AUPN353695A0 (en) 1995-06-14 1995-07-06 Commonwealth Scientific And Industrial Research Organisation Immunogenic preparation and method for improving the productivity of ruminant animals
WO1998007830A2 (en) * 1996-08-22 1998-02-26 The Institute For Genomic Research COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, $i(METHANOCOCCUS JANNASCHII)
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20030219467A1 (en) 2001-09-18 2003-11-27 The Board Of Regents Of The University Of Nebraska Method for the inhibition of methanogensis
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
AU2003222249A1 (en) * 2002-03-04 2003-09-22 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
SE523209C2 (sv) * 2002-05-14 2004-04-06 Akzo Nobel Nv Förfarande för att reducera metanbildningen från matspjälkningsaktiviteter hos djur
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
EP2203467B1 (en) * 2007-09-25 2016-12-14 Pastoral Greenhouse Gas Research LTD Phage -mru polynucleotides and polypeptides and uses thereof
CN101434924A (zh) * 2008-12-17 2009-05-20 中南大学 一种分离严格厌氧产甲烷古菌的方法
BR112012004308A2 (pt) * 2009-08-27 2015-09-01 Pastoral Greenhouse Gas Res Ltd Sequência do genoma completo do metanógeno methanobrevibacter ruminantium
CN101864362B (zh) * 2010-05-19 2012-05-09 江苏加德绿色能源有限公司 一种复合微生物菌剂及其应用
DE102011119230B4 (de) * 2011-11-23 2013-07-11 Audi Ag Kraftwagen-Blinkleuchte und Verfahren zum Betreiben einer Blinkleuchte
US20160002672A1 (en) * 2012-12-21 2016-01-07 Danisco Us Inc. Production of isoprene, isoprenoid, and isoprenoid precursors using an alternative lower mevalonate pathway

Also Published As

Publication number Publication date
AU2014210649A1 (en) 2014-09-04
AR068553A1 (es) 2009-11-18
BRPI0817312A2 (pt) 2015-03-17
US20210332087A1 (en) 2021-10-28
US8586709B2 (en) 2013-11-19
US20140220636A1 (en) 2014-08-07
MX2010003321A (es) 2010-08-03
CA2700164C (en) 2018-05-29
EP3327030A1 (en) 2018-05-30
RU2528854C2 (ru) 2014-09-20
EP2203467A4 (en) 2011-04-13
MX340736B (es) 2016-07-22
CL2008002861A1 (es) 2009-03-06
BRPI0817299A2 (pt) 2015-06-16
CN101918431B (zh) 2014-10-08
EP2203470A4 (en) 2011-04-13
JP5558356B2 (ja) 2014-07-23
EP2203466A4 (en) 2011-04-13
AR068551A1 (es) 2009-11-18
CA2700129A1 (en) 2009-04-02
AU2008304018A1 (en) 2009-04-02
CA2700162A1 (en) 2009-04-02
WO2009041832A2 (en) 2009-04-02
ES2895908T3 (es) 2022-02-23
DK2203466T3 (en) 2016-07-25
ES2625144T3 (es) 2017-07-18
CL2008002860A1 (es) 2009-06-05
US8592556B2 (en) 2013-11-26
AR068552A1 (es) 2009-11-18
WO2009041832A9 (en) 2009-10-22
JP6067209B2 (ja) 2017-01-25
RU2010116163A (ru) 2011-11-10
US20100209998A1 (en) 2010-08-19
MX2010003328A (es) 2010-08-16
WO2009041830A9 (en) 2009-08-27
US20100209999A1 (en) 2010-08-19
JP2017046704A (ja) 2017-03-09
EP2203466B1 (en) 2016-04-06
CN107129524A (zh) 2017-09-05
BR122021010737B1 (pt) 2021-09-21
AU2014210649B2 (en) 2016-09-08
NZ745324A (en) 2023-02-24
CA2700164A1 (en) 2009-04-02
AU2008305846A1 (en) 2009-04-02
AU2008304019A1 (en) 2009-04-02
DK2203467T3 (en) 2017-03-27
US11926647B2 (en) 2024-03-12
WO2009041831A1 (en) 2009-04-02
EP2203466A2 (en) 2010-07-07
JP2015042166A (ja) 2015-03-05
US20200325180A1 (en) 2020-10-15
JP2010539928A (ja) 2010-12-24
CN107129524B (zh) 2023-11-21
US9296789B2 (en) 2016-03-29
BRPI0817312B1 (pt) 2018-05-29
EP2203470A2 (en) 2010-07-07
CN101932595A (zh) 2010-12-29
WO2009041830A2 (en) 2009-04-02
US20170342112A1 (en) 2017-11-30
JP2010539927A (ja) 2010-12-24
US20100221185A1 (en) 2010-09-02
US10590170B2 (en) 2020-03-17
BRPI0817299A8 (pt) 2019-01-29
CA2700129C (en) 2021-07-20
DK3327030T3 (da) 2021-10-04
CL2008002859A1 (es) 2009-03-06
CN102015755A (zh) 2011-04-13
EP3936516A1 (en) 2022-01-12
WO2009041832A3 (en) 2009-06-11
WO2009041830A3 (en) 2009-07-02
ZA201001933B (en) 2013-10-30
UY31359A1 (es) 2009-04-30
JP5552053B2 (ja) 2014-07-16
US10995120B2 (en) 2021-05-04
EP3327030B1 (en) 2021-07-21
ES2587595T3 (es) 2016-10-25
MX2010003319A (es) 2010-09-10
UY31360A1 (es) 2009-04-30
JP2010539926A (ja) 2010-12-24
WO2009041831A9 (en) 2009-11-05
BR122020023381B1 (pt) 2021-09-08
CN101918431A (zh) 2010-12-15
EP2203467A1 (en) 2010-07-07
CN101932595B (zh) 2016-02-10
EP2203467B1 (en) 2016-12-14
BR122021010729B1 (pt) 2022-02-15
CA2700162C (en) 2018-08-14

Similar Documents

Publication Publication Date Title
UY31361A1 (es) Vacunas y componentes para inhibir celulas microbianas
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
CY1118797T1 (el) Ανταγωνιστες toll-ωδους υποδοχεα 3
CY1118250T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
CL2008000104A1 (es) Proteina de fusion que comprende un antigeno asociado a tumor (prame) o un fragmento inmunogenico de el y un derivado de proteina d; secuencia nucleotidica que codifica dicha proteina; vector y celula huesped que comprenden la proteina; vacuna que co
CR20120298A (es) Antagonistas de il-17a
CO6670523A2 (es) Anticuerpos específicos para proteína de activación fibroblástica (fap), polinucleotidos que codifican dichos anticuerpos, y vectores y células huesped que comprenden dichos nucleótidos
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CL2011002660A1 (es) Anticuerpo anti-receptor de activinas tipo iib (anti-actr-iib); secuencia de polinucleotidos aislados que codifica dicho anticuerpo; vector, celula huesped; composicion farmaceutica; uso para tratar transtornos musculo esqueleticos.
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
CL2012000752A1 (es) Compuestos derivados de fenilpiri(mi)dinilpirazoles para el control de microorganismos no deseados en la proteccion de plantas y compuestos intermediarios.
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
CL2008001879A1 (es) Compuestos derivados de isaxolinas-naftalen-carboamida; y el uso de los compuestos en el control de plagas de invertebrados en animales.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
CL2008000611A1 (es) Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
DK1791571T3 (da) Radiofluorinerede peptider
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CR11434A (es) Anticuerpos anti-amiloide humanos; composiciones, metodosy usos
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
UY32866A (es) Secuencia genómica completa del metanógeno methanobrevibacter ruminantium

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20210610